DYRK1A and prostate carcinoma: Based on the experimental data we found that, for example, kinases PIK3CG, NEK5, ERK3, NEK2, PIK3CA, PRKCE, CSNK2A2, PIM1, PKN2, and CAMK2D are enriched in non-small lung carcinoma A549 cell line while kinases DYRK1B, PCTK1, HIPK1, ICK, CDKL5, DYRK1A, MAK, ERK8, CLK1, and CLK2 are enriched in prostate carcinoma VCAP cell line.